Towa Pharmaceutical Co., Ltd. (4553.T) Stock
Towa Pharmaceutical Co., Ltd.

Company profile
Its largest business segment, Domestic, brought in 79% of segment revenue in fiscal year 2025; Japan was the largest region with 75%. Towa Pharmaceutical reports about 4,923 full-time employees.
Figures from company filings; latest fiscal year ended March 31, 2026.
About Towa Pharmaceutical Co., Ltd.
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of quasi drugs. In addition, it is involved in research and development and production of active pharmaceutical ingredients, intermediates, and support business; and planning, development and OEM manufacturing of health foods, pharmaceuticals, general foods, and other miscellaneous merchandizes. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Kadoma, Japan.
Largest shareholders
- Yoshida Family39.02 %39.02%
- Sumitomo Mitsui DS Asset Management Co., Ltd.6.23%
- Towa Pharmaceutical Co., Ltd.4.44%
- Towa Pharmaceutical Business Association2.99%
- Itsuro Yoshida2.824 %2.82%
Share of the company, as of September 25, 2026
Leadership
- Itsuro Yoshida — President & Representative Director, 74
- Shiro Hatagami — Executive Officer and Head of Accounting & Finance Division
- Tetsuo Yamashita — Operating Officer, Plant Manager of Okayama Plant & GM of Administration Department
- Masaji Morikawa — Operating Officer & Division Manager of Sales and Marketing Division
- Shigeki Fujita — Operating Officer & GM of Human Resource Development Center
What is Towa Pharmaceutical's largest business segment?
Domestic, with 206.10 billion JPY or 79% of segment revenue in fiscal year 2025. Next: Overseas (21%).
Where does Towa Pharmaceutical make most of its revenue?
Japan: 75% of revenue by region in fiscal year 2025, followed by Abroad (25%).
What companies are similar to Towa Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Nippon Shinyaku Co., Ltd. (4516.T), Sawai Group Holdings Co., Ltd. (4887.T), Nxera Pharma Co., Ltd. (4565.T), Kissei Pharmaceutical Co., Ltd. (4547.T).
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Towa Pharmaceutical Co., Ltd. (4553.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4553.T